<DOC>
	<DOC>NCT01624207</DOC>
	<brief_summary>The generic formulation of atorvastatin (Atorva®) 20mg was not inferior to the branded formulation of atorvastatin (Lipitor®) 20mg in this 8-week treatment of hyperlipidemic Korean patients. In PP analysis, the LDL cholesterol goal achievement rate was significantly higher in Atorva group. Both treatments were well tolerated.</brief_summary>
	<brief_title>The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Eligible patients were men or women aged between 20 and 79 years who have not achieved LDL cholesterol goals using the National Cholesterol Education Program Adult Treatment Panel Ⅲ (NCEPATP Ⅲ) guideline, with the treatment goal of LDL cholesterol being &lt;100 mg/dL for patients with coronary artery disease (CAD) or CADequivalent disease, &lt;130 mg/dL for patients with multiple risk factors (10year coronary heart disease [CHD] risk ≤20%), and &lt;160 mg/dL for patients with 0 to 1 risk factors. Exclusion criteria were as follows: currently taking any kind of antihyperlipidemic drug (within 4 weeks before enrollment); hypersensitivity or intolerance to atorvastatin or other HMGCoA reductase inhibitor; newly diagnosed (within 3 months before enrollment) or uncontrolled diabetes (hemoglobin A1C &gt;9%); uncontrolled hypertension (systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;100 mmHg); hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels ≥2 times the upper limit of normal [ULN]); an unexplained serum creatinine kinase (CK) elevation &gt;2 times the ULN, chronic renal failure (a serum creatinine concentration &gt;2.5 mg/dL); in patients who experienced operation at the time of screening, the patients must have a result of lipid profiles within 24 hours or after 6 weeks; a history of malignancy or cervical dysplasia; pregnant or breastfeeding women; women of childbearing potential had to be using adequate methods of contraception; a history of drug abuse or alcoholism; participation in other studies 4 weeks before enrollment. Patients could also be excluded if their participation was considered inappropriate by the study physician.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Atorva</keyword>
	<keyword>generic</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>